Compare CLDT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDT | ALLO |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 597.5M | 707.6M |
| IPO Year | N/A | 2018 |
| Metric | CLDT | ALLO |
|---|---|---|
| Price | $13.36 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $11.00 | $8.35 |
| AVG Volume (30 Days) | 389.3K | ★ 10.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | $610.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.08 | $0.99 |
| 52 Week High | $13.64 | $4.46 |
| Indicator | CLDT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 35.67 |
| Support Level | $6.26 | $1.56 |
| Resistance Level | $13.64 | $1.92 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 78.33 | 6.86 |
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania, among others. Substantially all of the company's assets are held and operated by its operating partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. Chatham's revenue streams include room, food and beverage, and other. The room comprises the majority of its total revenue. Chatham's hotels operate under various brands, which include Hilton, Marriott, and Hyatt.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).